A new drug for pancreatic cancer has been approved in the United States, marking a significant breakthrough in the treatment of this often difficult-to-treat disease.
Europe is preparing to follow the same path, with approval of the drug expected on the European continent in the near future.
The cost of treatment is high, at around 34,000 euros for each month of therapy, raising questions about the accessibility of the drug for patients.
Clinical trials have shown that the drug doubled patients' survival rate, representing a substantial improvement in the outlook for people diagnosed with this type of cancer.




